mCRPC

22 clinical trials · Condition

Record	Firm	Date
Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection (NCT05413850)	Blue Earth Therapeutics Ltd	2022-07-20
Cabazitaxel in Combination With 177Lu-PSMA-617 in Metastatic Castration-resistant Prostate Cancer (NCT05340374)	Peter MacCallum Cancer Centre, Australia	2022-07-14
Senaparib in mCRPC Patients With Homologous Recombination Repair Gene Alterations After Docetaxel Treatment (NCT04822961)	Impact Therapeutics, Inc.	2021-12-31
A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, Dosimetry, and Anti-tumor Activity of Ga-68-NGUL / Lu-177-DGUL in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Refractory to Standard Therapy (NCT05547061)	Cellbion Co., Ltd.	2021-04-12
Performance of 177Lu-PSMA-I&T for RLT in mCRPC - Prospective Multicenter Swiss Registry Study (NCT06830408)	University Hospital, Basel, Switzerland	2020-07-06
Continuation Protocol for ZEN003694 in Patients Experiencing Clinical Benefit While Enrolled in a ZEN003694 Protocol (NCT04145375)	Zenith Epigenetics	2019-11-12
A Trial Evaluating the Efficacy and Safety of HC-1119 Soft Capsules in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC). (NCT03851640)	Hinova Pharmaceuticals Inc.	2019-04-12
Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC (NCT03395197)	Pfizer	2017-12-18
A Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion Cohorts (NCT02266745)	Promontory Therapeutics Inc.	2014-07-01
Sipuleucel-T and Stereotactic Ablative Body Radiation (SABR) for Metastatic Castrate-resistant Prostate Cancer (mCRPC) (NCT01818986)	University of Texas Southwestern Medical Center	2013-07-10

Track mCRPC automatically

Every clearance here is in the API, with alerts when new ones post.